Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.

Abstract

In Japan, the use of amantadine for treatment of influenza A virus infection was not accepted until November 1998, although it was widely used for treatment of Parkinsonism. Since then, we have monitored the emergence of amantadine-resistant viruses and isolated two viruses from patients on long-term treatment with amantadine.

• Authors: J Iwahashi, K Tsuji, T Ishibashi, J Kajiwara, Y Imamura, R Mori, K Hara, T Kashiwagi, Y Ohtsu, N Hamada, H Maeda, M Toyoda, T Toyoda
• Journal: Journal of clinical microbiology (J Clin Microbiol) Vol. 39 Issue 4 Pg. 1652-3 (Apr 2001) ISSN: 0095-1137 [Print] United States
• PMID: 11283109 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiparkinson Agents
• Antiviral Agents
• Amantadine

Topics

• Aged
• Aged, 80 and over
• Amantadine (pharmacology, therapeutic use)
• Antiparkinson Agents (pharmacology, therapeutic use)
• Antiviral Agents (pharmacology, therapeutic use)
• Cerebral Infarction (complications)
• Drug Resistance, Microbial
• Humans
• Influenza A Virus, H3N2 Subtype
• Influenza A virus (drug effects, isolation & purification)
• Influenza, Human (drug therapy, prevention & control, virology)
• Japan
• Molecular Sequence Data
• Parkinson Disease (drug therapy)
• Syndrome